← SynDRA
ZAFIRLUKAST
SynDRA canonical compound SYN0001085 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | CYSLTR1 |
|---|
| Mechanism of action | Leukotriene receptor antagonist |
|---|
| Indication | asthma |
|---|
| Disease area | pulmonary |
|---|
All known targets
- CYSLTR1
- CYSLTR2
- EPHX2
- PPARG
- ADORA3
- PLA2G4A
- SLC47A2
- SLC47A1
- SLC22A2
- SLC10A1
- PTGES
- MAPK14
Mechanisms of action (all sources)
- Leukotriene receptor antagonist
- CYSLTR1 ANTAGONIST
- Cysteinyl leukotriene receptor 1 antagonist
- CYSLTR2 ANTAGONIST
- EPHX2 INHIBITOR
- PPARG AGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB11
- ADRA2A
- PDE4D
- OPRK1
- NR1I3
- NR1I2
- NR1H4
- ESR2
- XPO1
- ADRA1A
- ADRA1D
- ADORA1
- NPY1R
- NPY2R
- NR1H2
- NR1H3
- ADORA2A
- ADGRF1
- HTR3A
- NR3C1
- NTHL1
- OGG1
- OPRD1
- ACHE
- OPRM1
- NPSR1
- NEIL2
- NEIL1
- MUTYH
- MPG
- MMP9
- MMP1
- MLNR
- MC5R
- MC4R
- MC3R
- MBD4
- MAPT
- MAOA
- LCK
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- AHR
- NTMT1
- LRC26
- MK01
- NF2L2
- NFE2L2
- NOD1
- NRP2
- NTM1A
- PPM1D
- KCNQ1
- PPP1CA
- RAPGEF3
- RAPGEF4
- RPGF3
- RPGF4
- SAE1
- UBA2
- KEAP1
- KCMB4
- ALR
- CP3A4
- ANDR
- ATXN2
- B2CL1
- CAC1B
- CAC1H
- CLTR2
- CP2C9
- CP3A7
- KCMB2
- DPOLB
- GCR
- GEMI
- GPX4
- IF4H
- KCMA1
- KCMB1
- UBP1
Drug classes
- Leukotriene Receptor Antagonists
- Anti-Asthmatic Agents
- Hormone Antagonists
- Leukotriene Antagonists
- Respiratory System Agents
- Leukotriene Receptor Antagonist
- Cytochrome P450 2C9 Inhibitors
ATC classes
- R03D · OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Cross-references
Synonyms
- ACCOLATE
- Accolate
- ICI 204219
- ICI 204,219
- vanticon
- ICI-204219
- Accoleit
- Aeronix
- Olmoran
- Respix
- Zafirst
- AstraZeneca brand of zafirlukast
- Menarini brand of zafirlukast
- Novartis brand of zafirlukast
- Zeneca brand of zafirkulast
- Accolate (TN)
- Accoleit (TN)
- Vanticon (TN)
- Zafirlukast [USAN:BAN:INN]
- Accolate, Accoleit, Vanticon, Zafirlukast
- Zafirlukast (JAN/USAN/INN)
- ICI-204,219
- XZ629S5L50
- DTXCID303746
- CHEBI:10100
- zafirlukastum
- RefChem:57963
- R03DC01
- MFCD00864775
- NCGC00164547-01
- NCGC00164547-06
- Vanticon
- SMR000466316
- CAS-107753-78-6
- SR-01000759386
- UNII-XZ629S5L50
- Zafirlukast [USAN:INN:BAN]
Reported adverse events
- Asthenia
- Dizziness
- Dyspepsia
- Hepatotoxicity
- Hypersensitivity
- Infection
- Myalgia
- Nausea
- Vomiting
- Headache
Look up ZAFIRLUKAST in the interactive SynDRA portal →